Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
The Conversation logo

The fight against COVID-19 has launched a thousand military metaphors in the British press. The “greatest challenge since the Second World War”, “the frontline”, the virus is an “invisible enemy”, and so forth. Us citizens feel besieged and under threat as we retreat to our foxholes.

If this is a war, how is Britain doing? The frontline troops are running out of protective gear (PPE), ammunition (beds) and heavy equipment (ventilators). Supply lines are stretched thin. Meanwhile, the country’s leadership – the prime minister, secretary of state for health and the chief medical officer – are self-isolated in their bunkers where they cannot be functioning at 100%.

Read the full article on The Conversation website, written by Professor David Hunter (Big Data Institute, Nuffield Department of Population Health).

Oxford is a subscribing member of The ConversationFind out how you can write for The Conversation.

Similar stories

Oxford vaccine creator Professor Sarah Gilbert awarded RSA Albert Medal

Awards and Appointments Coronavirus COVID-19 General Innovation Research

Professor Sarah Gilbert has been awarded the Royal Society for Arts, Manufactures and Commerce’ (RSA) Albert Medal for her work on the Oxford vaccine.

PRINCIPLE Covid-19 treatments trial widens to under 50s and adds colchicine

Clinical Trials Coronavirus COVID-19 General Research

From today, the UK’s national priority platform trial of Covid-19 treatments for recovery at home launches its investigation of the gout drug colchicine, and expands for the first time to include adults of any age.

New data show vaccines reduce severe COVID-19 in older adults

Coronavirus COVID-19 Research

New data show both Oxford / AstraZeneca vaccine and the Pfizer-BioNTech vaccines significantly reduce severe COVID-19 in older adults.

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.